Libo Pharma Corp.
TTPEX:788829.00
TWD
+0.10
(+0.35%)
Libo Pharma Corp.
TPEX:7888
(Taipei Exchange)
Recent
price
29.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Libo Pharma Corp. is a Taiwan-based biopharmaceutical company engaged in the research, development, and commercialization of specialty pharmaceutical products and advanced drug delivery formulations. The company focuses on oncology therapeutics, complex injectable formulations, and proprietary lipid-based nanoparticle delivery technologies. Its core product and service portfolio includes: targeted oncology therapeutics for solid tumors and hematological indications; liposome-encapsulated and nanoparticle formulation platforms engineered to optimize drug bioavailability, stability, and targeted biodistribution; specialty injectable medications for pain management, anti-infective treatment, and acute care; 505(b)(2) modified-release formulations and improved therapeutic entities; and contract formulation development, preclinical research, and technical licensing services for specialized drug delivery systems. Libo Pharma Corp. primarily serves medical centers, healthcare providers, and global pharmaceutical corporations across the biopharmaceutical and clinical healthcare sectors. The company maintains research, development, and operational facilities in Taiwan and pursues clinical development and regulatory filings across Asia, North America, and international markets. Founded in Taiwan and headquartered in Taipei, Taiwan, the company trades on the Taipei Exchange under the ticker symbol 7888. In recent developments, Libo Pharma Corp. completed its public registration and listing on the Taipei Exchange Emerging Stock Board to expand its institutional investor base and fund late-stage clinical programs. In addition, the company has advanced its clinical pipeline through multi-center trial authorizations and regulatory submissions, entered into strategic co-development and licensing alliances with regional biopharmaceutical partners, and expanded its specialized formulation development and analytical facilities to accelerate the commercialization of its proprietary therapeutic pipeline.